IDWeek (2019), 2–6 October 2019, Washington DC
18 October 2019. Related: Conference reports.
IDWeek 2019
HIV suppression and safety with ibalizumab at 48 weeks in expanded access
18 October 2019. Related: Conference reports, Antiretrovirals.
Oral cabotegravir and rilpivirine is durable for 5.5 years in LATTE study
18 October 2019. Related: Conference reports, Antiretrovirals.
Dolutegravir plus rilpivirine had good virologic, safety record in clinics before single tablet available
18 October 2019. Related: Conference reports, Antiretrovirals.
Switching from TDF to TAF linked to higher BMI and cardio risk
18 October 2019. Related: Conference reports, Antiretrovirals, Side effects.
Over half of mostly black US HIV group has NAFLD – and many have NASH
18 October 2019. Related: Conference reports, Lipodystrophy and metabolic complications.
People taking more medications and women have higher fall risk in older HIV group
18 October 2019. Related: Conference reports, Coinfections and complications, Ageing and life expectancy.
PrEP linked to lower HIV incidence in US, independent of TasP
18 October 2019. Related: Conference reports, HIV prevention and transmission.
